Antigen-specific T-cells prepared by culturing T-cells in formulationscomprising combinations of DCs and either tumor cells or virally infectedcells are disclosed. These formulations generally comprise hybridoma of atleast one dendritic cell fused to either at least one tumor cell or at leastone virally infected cell, or co-cultures of dendritic cells and either tumorcells or virally infected cells. The resulting T-cells can then be used inimmunotherapy methods through adoptive transfer of autologous antigen-specificT-cells into patients using well-established techniques, as agents to identifytumor antigens, and to establish animal models.
展开▼
